2026 Q2 - tulosraportti
37 päivää sitten
‧42 min
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 224 | NON | DDB | ||
| 76 | NON | DDB | ||
| 195 | SSWM | PAS | ||
| 100 | SSWM | DDB | ||
| 500 | SSWM | PAS |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Rahastot ja ETF:t, joilla on osaketta
Mikään rahasto ei ilmoita osaketta kymmenen suurimman omistuksensa joukossa.
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q3 - tulosraportti 26.11. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q2 - tulosraportti 31.8. | ||
2026 Q1 - tulosraportti 29.5. | ||
2025 Q4 - tulosraportti 26.2. | ||
2025 Q3 - tulosraportti 1.12.2025 | ||
2025 Q2 - tulosraportti 28.8.2025 |
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
·6 t sittenSo the recruitment of _10_ patients for the uBBB cohort is underway 🙏🏻
You can ask yourself this question.....is a mcap of 444 mio dkk a high or low price at the present time.
2 päivää sittenCurasight resumes patient enrolment in Phase 1 glioblastoma study following approval of protocol amendment Close i dag kl. 08:41 ∙ Cision Copenhagen, Denmark, 5 October 2026 - Curasight A/S ("Curasight" or the "Company" - TICKER: CURAS), a clinical-stage radiopharmaceutical company developing uPAR-targeted radiopharmaceuticals for therapy, diagnostics and supporting imaging, today announces that the protocol amendment for its ongoing Phase 1 clinical trial in patients with glioblastoma has been approved by the relevant authorities. The study is designed to assess two important matters in support of Curasight's glioblastoma therapeutic program: i) evaluate uTREAT® to characterize tumor delivery, biodistribution and dosimetry and ii) to identify the most efficient delivery method using super-selective intra-arterial delivery. Patient enrolment under the amended protocol can therefore resume. The protocol amendment, announced in July 2026, is designed to optimize the delivery method and generate additional clinical information to support a robust dataset and inform subsequent therapeutic development. Under the amended protocol, newly enrolled patients will receive uTREAT® without mannitol-induced blood-brain barrier disruption. Ulrich Krasilnikoff, CEO of Curasight, commented: "We are very pleased that the amended protocol has now been approved and that patient enrolment can resume. The amendment reflects that we see the delivery method as an important feature of the program and underpins our data-driven approach. These data will help inform the subsequent dose-finding and phase 2 studies in the development of our glioblastoma program. We look forward to progressing enrolment and generating the additional data." As announced in Curasight's Interim Report Q2 2026, topline data from the Phase 1 glioblastoma study are expected in H1 2027. For more information regarding Curasight, please contact: Ulrich Krasilnikoff, CEO E-mail: uk@curasight.com
·3.10. · Muokattu🔥 12 pat. mBBB vs. 10 pat. uBBB - Now things are getting exciting! The past month has provided several important pieces in the Curasight case. uTREAT is ready for a restart with 10 uBBB patients! On September 30, the amended protocol was approved. The planned restart is October 23, but Ulrich said at H1 that they expect to be able to get started very soon once the regulatory approval is in place. Could this be the next FBM? There has been some uncertainty about how many mBBB patients have actually been treated. It is established that 12 mBBB patients have been treated in the first part of the uTREAT study. And that is far more important than it might initially sound. The 12 mBBB patients give Curasight a much stronger data foundation for uTREAT and make the direct comparison with the 10 upcoming uBBB patients very exciting. 1. The first 12 patients are mBBB Cohort 1 mBBB: • 6 patients • BBB was temporarily opened with mannitol. Cohort 2 mBBB: • March 24, the Phase I expansion with 6 patients was approved. • Tumor dose target raised from 60 Gy to >100 Gy. The first 12 patients are therefore mBBB patients, i.e. treated with mannitol/BBB disruption. 2. uBBB is a new cohort in the existing Phase I Curasight describes uBBB as a separate cohort in the existing Phase I uTREAT study. The purpose is simple: Compare uBBB with the first mBBB cohort and see what BBB disruption actually contributes. Andreas originally talked about 6 uBBB patients. Curasight later wrote "at least 6 patients". The approved SM-2 protocol in CTIS now says: 10 planned participants. 3. CTIS documents the shift to the new uBBB cohort 🎯 July 22, 2026, the trial was temporarily paused due to the substantial protocol amendments: • CTIS writes: "All participants have completed the study and there is no participant under treatment at the moment." • All new participants after the pause must be treated according to the revised protocol. • This documents the shift between the existing mBBB part and the new uBBB cohort. • There are no uBBB patients among the participants who had already completed. uBBB only comes with the revised protocol. The CTIS course: Protocol version Planned participants Initial 6 SM-1 6 SM-2 10 The numbers are not cumulative. They show the planned number of patients in the individual protocol version. 4. Timing is important In June 2026, Curasight came out with encouraging interim data: • high tumor uptake • retention in tumor • dosimetry compatible with therapeutically relevant radiation dose • no exceeding of dose limits for healthy organs • continued development. Then comes the capital raise of approx. 20 million DKK. Curasight writes directly: "Following these results". The capital is to support the continued development of uTRACE and uTREAT towards H1 2027. 5. The protocol amendment in July Curasight describes the amendment as being based on "experience gained during the ongoing trial". The purpose is to "strengthen the scientific value of the study." The new uBBB cohort is to be compared with the first mBBB cohort. Thus, it is the experiences from the ongoing mBBB cohort that lie behind the change. Curasight uses the new data to investigate whether the treatment can be made simpler without losing the necessary tumor delivery. It is not a "we got bad data, so we are trying again" signal. They have obtained new data and are testing the next question. 6. So what do the 10 pat. uBBB mean? Andreas originally talked about 6 uBBB patients. Curasight later wrote "at least 6 patients". Now the approved SM-2 protocol says 10 planned participants. 6 was the minimum and now the number is 10. The simple explanation is that Curasight has chosen a larger data foundation for the comparison with the 12 pat. mBBB. This fits well with the formulation "strengthen the scientific value of the study." 10 pat. uBBB simply provide a stronger data foundation than 6 pat. It makes the comparison far more stringent. 7. The Golden Nugget 💰 12 pat. mBBB + 10 pat. uBBB gives Curasight the opportunity to compare the two groups directly and answer a very concrete and strongly value-driving question: Is BBB opening actually necessary for uTREAT? If uBBB shows that the same tumor delivery can be achieved without mannitol, it doesn't just change the treatment – it changes the product. uTREAT then becomes a significantly simpler and less burdensome treatment for glioblastoma, which can be given to a broader group of patients and be far easier to implement in clinical practice. It is an entirely different commercial case. Big Pharma does not just pay for a therapeutic radioligand product to work. They pay for the value the product creates - and this is precisely where the value is significantly boosted. We have received positive readout data, and exciting topline data is on the way in H1. The case is not just intact - but stands before a massive change in value! 🚀 Data is King - we need to see it! ⚡
Information hierarchy..!! 😁 Who the f..... Cares about that One must say that there are enough Alphas here to write a folkeskole ADHD textbook, but is there anyone who can give me an answer on whether this "Case" IH holds up or should I just buy a John Deere!!! Thinking the latter atm- ·1.10.InStock pointed out that the protocol change has now been approved (30/9). Now it will be exciting to hear the wording / PM of this - and then it is just to get started 😉Why on earth is there not coming any PM/BM from management? There is practically radio silence. An announcement about the approval could at least come. Or is it not big enough and worth the trouble?
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tuotteita joiden kohde-etuutena tämä arvopaperi
Välittäjätilasto
Ostaneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Nordnet Bank AB | 13 025 | 1 167 | 11 858 | 97 |
| SSW Market Making GmbH | 9 647 | 9 442 | 205 | 0 |
| Avanza Bank AB | 0 | 249 | −249 | 0 |
| Pareto Securities AS | 3 393 | 6 073 | −2 680 | 0 |
| Danske Bank A/S | 660 | 9 794 | −9 134 | 0 |
Myyneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Danske Bank A/S | 660 | 9 794 | −9 134 | 0 |
| Pareto Securities AS | 3 393 | 6 073 | −2 680 | 0 |
| Avanza Bank AB | 0 | 249 | −249 | 0 |
| SSW Market Making GmbH | 9 647 | 9 442 | 205 | 0 |
| Nordnet Bank AB | 13 025 | 1 167 | 11 858 | 97 |
2026 Q2 - tulosraportti
37 päivää sitten
‧42 min
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
- ·6 t sittenSo the recruitment of _10_ patients for the uBBB cohort is underway 🙏🏻You can ask yourself this question.....is a mcap of 444 mio dkk a high or low price at the present time.
- 2 päivää sittenCurasight resumes patient enrolment in Phase 1 glioblastoma study following approval of protocol amendment Close i dag kl. 08:41 ∙ Cision Copenhagen, Denmark, 5 October 2026 - Curasight A/S ("Curasight" or the "Company" - TICKER: CURAS), a clinical-stage radiopharmaceutical company developing uPAR-targeted radiopharmaceuticals for therapy, diagnostics and supporting imaging, today announces that the protocol amendment for its ongoing Phase 1 clinical trial in patients with glioblastoma has been approved by the relevant authorities. The study is designed to assess two important matters in support of Curasight's glioblastoma therapeutic program: i) evaluate uTREAT® to characterize tumor delivery, biodistribution and dosimetry and ii) to identify the most efficient delivery method using super-selective intra-arterial delivery. Patient enrolment under the amended protocol can therefore resume. The protocol amendment, announced in July 2026, is designed to optimize the delivery method and generate additional clinical information to support a robust dataset and inform subsequent therapeutic development. Under the amended protocol, newly enrolled patients will receive uTREAT® without mannitol-induced blood-brain barrier disruption. Ulrich Krasilnikoff, CEO of Curasight, commented: "We are very pleased that the amended protocol has now been approved and that patient enrolment can resume. The amendment reflects that we see the delivery method as an important feature of the program and underpins our data-driven approach. These data will help inform the subsequent dose-finding and phase 2 studies in the development of our glioblastoma program. We look forward to progressing enrolment and generating the additional data." As announced in Curasight's Interim Report Q2 2026, topline data from the Phase 1 glioblastoma study are expected in H1 2027. For more information regarding Curasight, please contact: Ulrich Krasilnikoff, CEO E-mail: uk@curasight.com
- ·3.10. · Muokattu🔥 12 pat. mBBB vs. 10 pat. uBBB - Now things are getting exciting! The past month has provided several important pieces in the Curasight case. uTREAT is ready for a restart with 10 uBBB patients! On September 30, the amended protocol was approved. The planned restart is October 23, but Ulrich said at H1 that they expect to be able to get started very soon once the regulatory approval is in place. Could this be the next FBM? There has been some uncertainty about how many mBBB patients have actually been treated. It is established that 12 mBBB patients have been treated in the first part of the uTREAT study. And that is far more important than it might initially sound. The 12 mBBB patients give Curasight a much stronger data foundation for uTREAT and make the direct comparison with the 10 upcoming uBBB patients very exciting. 1. The first 12 patients are mBBB Cohort 1 mBBB: • 6 patients • BBB was temporarily opened with mannitol. Cohort 2 mBBB: • March 24, the Phase I expansion with 6 patients was approved. • Tumor dose target raised from 60 Gy to >100 Gy. The first 12 patients are therefore mBBB patients, i.e. treated with mannitol/BBB disruption. 2. uBBB is a new cohort in the existing Phase I Curasight describes uBBB as a separate cohort in the existing Phase I uTREAT study. The purpose is simple: Compare uBBB with the first mBBB cohort and see what BBB disruption actually contributes. Andreas originally talked about 6 uBBB patients. Curasight later wrote "at least 6 patients". The approved SM-2 protocol in CTIS now says: 10 planned participants. 3. CTIS documents the shift to the new uBBB cohort 🎯 July 22, 2026, the trial was temporarily paused due to the substantial protocol amendments: • CTIS writes: "All participants have completed the study and there is no participant under treatment at the moment." • All new participants after the pause must be treated according to the revised protocol. • This documents the shift between the existing mBBB part and the new uBBB cohort. • There are no uBBB patients among the participants who had already completed. uBBB only comes with the revised protocol. The CTIS course: Protocol version Planned participants Initial 6 SM-1 6 SM-2 10 The numbers are not cumulative. They show the planned number of patients in the individual protocol version. 4. Timing is important In June 2026, Curasight came out with encouraging interim data: • high tumor uptake • retention in tumor • dosimetry compatible with therapeutically relevant radiation dose • no exceeding of dose limits for healthy organs • continued development. Then comes the capital raise of approx. 20 million DKK. Curasight writes directly: "Following these results". The capital is to support the continued development of uTRACE and uTREAT towards H1 2027. 5. The protocol amendment in July Curasight describes the amendment as being based on "experience gained during the ongoing trial". The purpose is to "strengthen the scientific value of the study." The new uBBB cohort is to be compared with the first mBBB cohort. Thus, it is the experiences from the ongoing mBBB cohort that lie behind the change. Curasight uses the new data to investigate whether the treatment can be made simpler without losing the necessary tumor delivery. It is not a "we got bad data, so we are trying again" signal. They have obtained new data and are testing the next question. 6. So what do the 10 pat. uBBB mean? Andreas originally talked about 6 uBBB patients. Curasight later wrote "at least 6 patients". Now the approved SM-2 protocol says 10 planned participants. 6 was the minimum and now the number is 10. The simple explanation is that Curasight has chosen a larger data foundation for the comparison with the 12 pat. mBBB. This fits well with the formulation "strengthen the scientific value of the study." 10 pat. uBBB simply provide a stronger data foundation than 6 pat. It makes the comparison far more stringent. 7. The Golden Nugget 💰 12 pat. mBBB + 10 pat. uBBB gives Curasight the opportunity to compare the two groups directly and answer a very concrete and strongly value-driving question: Is BBB opening actually necessary for uTREAT? If uBBB shows that the same tumor delivery can be achieved without mannitol, it doesn't just change the treatment – it changes the product. uTREAT then becomes a significantly simpler and less burdensome treatment for glioblastoma, which can be given to a broader group of patients and be far easier to implement in clinical practice. It is an entirely different commercial case. Big Pharma does not just pay for a therapeutic radioligand product to work. They pay for the value the product creates - and this is precisely where the value is significantly boosted. We have received positive readout data, and exciting topline data is on the way in H1. The case is not just intact - but stands before a massive change in value! 🚀 Data is King - we need to see it! ⚡Information hierarchy..!! 😁 Who the f..... Cares about that One must say that there are enough Alphas here to write a folkeskole ADHD textbook, but is there anyone who can give me an answer on whether this "Case" IH holds up or should I just buy a John Deere!!! Thinking the latter atm
- ·1.10.InStock pointed out that the protocol change has now been approved (30/9). Now it will be exciting to hear the wording / PM of this - and then it is just to get started 😉Why on earth is there not coming any PM/BM from management? There is practically radio silence. An announcement about the approval could at least come. Or is it not big enough and worth the trouble?
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 224 | NON | DDB | ||
| 76 | NON | DDB | ||
| 195 | SSWM | PAS | ||
| 100 | SSWM | DDB | ||
| 500 | SSWM | PAS |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Rahastot ja ETF:t, joilla on osaketta
Mikään rahasto ei ilmoita osaketta kymmenen suurimman omistuksensa joukossa.
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q3 - tulosraportti 26.11. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q2 - tulosraportti 31.8. | ||
2026 Q1 - tulosraportti 29.5. | ||
2025 Q4 - tulosraportti 26.2. | ||
2025 Q3 - tulosraportti 1.12.2025 | ||
2025 Q2 - tulosraportti 28.8.2025 |
Tuotteita joiden kohde-etuutena tämä arvopaperi
Välittäjätilasto
Ostaneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Nordnet Bank AB | 13 025 | 1 167 | 11 858 | 97 |
| SSW Market Making GmbH | 9 647 | 9 442 | 205 | 0 |
| Avanza Bank AB | 0 | 249 | −249 | 0 |
| Pareto Securities AS | 3 393 | 6 073 | −2 680 | 0 |
| Danske Bank A/S | 660 | 9 794 | −9 134 | 0 |
Myyneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Danske Bank A/S | 660 | 9 794 | −9 134 | 0 |
| Pareto Securities AS | 3 393 | 6 073 | −2 680 | 0 |
| Avanza Bank AB | 0 | 249 | −249 | 0 |
| SSW Market Making GmbH | 9 647 | 9 442 | 205 | 0 |
| Nordnet Bank AB | 13 025 | 1 167 | 11 858 | 97 |
2026 Q2 - tulosraportti
37 päivää sitten
‧42 min
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q3 - tulosraportti 26.11. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q2 - tulosraportti 31.8. | ||
2026 Q1 - tulosraportti 29.5. | ||
2025 Q4 - tulosraportti 26.2. | ||
2025 Q3 - tulosraportti 1.12.2025 | ||
2025 Q2 - tulosraportti 28.8.2025 |
Tuotteita joiden kohde-etuutena tämä arvopaperi
Foorumi
Liity keskusteluun Nordnet Socialissa
- ·6 t sittenSo the recruitment of _10_ patients for the uBBB cohort is underway 🙏🏻You can ask yourself this question.....is a mcap of 444 mio dkk a high or low price at the present time.
- 2 päivää sittenCurasight resumes patient enrolment in Phase 1 glioblastoma study following approval of protocol amendment Close i dag kl. 08:41 ∙ Cision Copenhagen, Denmark, 5 October 2026 - Curasight A/S ("Curasight" or the "Company" - TICKER: CURAS), a clinical-stage radiopharmaceutical company developing uPAR-targeted radiopharmaceuticals for therapy, diagnostics and supporting imaging, today announces that the protocol amendment for its ongoing Phase 1 clinical trial in patients with glioblastoma has been approved by the relevant authorities. The study is designed to assess two important matters in support of Curasight's glioblastoma therapeutic program: i) evaluate uTREAT® to characterize tumor delivery, biodistribution and dosimetry and ii) to identify the most efficient delivery method using super-selective intra-arterial delivery. Patient enrolment under the amended protocol can therefore resume. The protocol amendment, announced in July 2026, is designed to optimize the delivery method and generate additional clinical information to support a robust dataset and inform subsequent therapeutic development. Under the amended protocol, newly enrolled patients will receive uTREAT® without mannitol-induced blood-brain barrier disruption. Ulrich Krasilnikoff, CEO of Curasight, commented: "We are very pleased that the amended protocol has now been approved and that patient enrolment can resume. The amendment reflects that we see the delivery method as an important feature of the program and underpins our data-driven approach. These data will help inform the subsequent dose-finding and phase 2 studies in the development of our glioblastoma program. We look forward to progressing enrolment and generating the additional data." As announced in Curasight's Interim Report Q2 2026, topline data from the Phase 1 glioblastoma study are expected in H1 2027. For more information regarding Curasight, please contact: Ulrich Krasilnikoff, CEO E-mail: uk@curasight.com
- ·3.10. · Muokattu🔥 12 pat. mBBB vs. 10 pat. uBBB - Now things are getting exciting! The past month has provided several important pieces in the Curasight case. uTREAT is ready for a restart with 10 uBBB patients! On September 30, the amended protocol was approved. The planned restart is October 23, but Ulrich said at H1 that they expect to be able to get started very soon once the regulatory approval is in place. Could this be the next FBM? There has been some uncertainty about how many mBBB patients have actually been treated. It is established that 12 mBBB patients have been treated in the first part of the uTREAT study. And that is far more important than it might initially sound. The 12 mBBB patients give Curasight a much stronger data foundation for uTREAT and make the direct comparison with the 10 upcoming uBBB patients very exciting. 1. The first 12 patients are mBBB Cohort 1 mBBB: • 6 patients • BBB was temporarily opened with mannitol. Cohort 2 mBBB: • March 24, the Phase I expansion with 6 patients was approved. • Tumor dose target raised from 60 Gy to >100 Gy. The first 12 patients are therefore mBBB patients, i.e. treated with mannitol/BBB disruption. 2. uBBB is a new cohort in the existing Phase I Curasight describes uBBB as a separate cohort in the existing Phase I uTREAT study. The purpose is simple: Compare uBBB with the first mBBB cohort and see what BBB disruption actually contributes. Andreas originally talked about 6 uBBB patients. Curasight later wrote "at least 6 patients". The approved SM-2 protocol in CTIS now says: 10 planned participants. 3. CTIS documents the shift to the new uBBB cohort 🎯 July 22, 2026, the trial was temporarily paused due to the substantial protocol amendments: • CTIS writes: "All participants have completed the study and there is no participant under treatment at the moment." • All new participants after the pause must be treated according to the revised protocol. • This documents the shift between the existing mBBB part and the new uBBB cohort. • There are no uBBB patients among the participants who had already completed. uBBB only comes with the revised protocol. The CTIS course: Protocol version Planned participants Initial 6 SM-1 6 SM-2 10 The numbers are not cumulative. They show the planned number of patients in the individual protocol version. 4. Timing is important In June 2026, Curasight came out with encouraging interim data: • high tumor uptake • retention in tumor • dosimetry compatible with therapeutically relevant radiation dose • no exceeding of dose limits for healthy organs • continued development. Then comes the capital raise of approx. 20 million DKK. Curasight writes directly: "Following these results". The capital is to support the continued development of uTRACE and uTREAT towards H1 2027. 5. The protocol amendment in July Curasight describes the amendment as being based on "experience gained during the ongoing trial". The purpose is to "strengthen the scientific value of the study." The new uBBB cohort is to be compared with the first mBBB cohort. Thus, it is the experiences from the ongoing mBBB cohort that lie behind the change. Curasight uses the new data to investigate whether the treatment can be made simpler without losing the necessary tumor delivery. It is not a "we got bad data, so we are trying again" signal. They have obtained new data and are testing the next question. 6. So what do the 10 pat. uBBB mean? Andreas originally talked about 6 uBBB patients. Curasight later wrote "at least 6 patients". Now the approved SM-2 protocol says 10 planned participants. 6 was the minimum and now the number is 10. The simple explanation is that Curasight has chosen a larger data foundation for the comparison with the 12 pat. mBBB. This fits well with the formulation "strengthen the scientific value of the study." 10 pat. uBBB simply provide a stronger data foundation than 6 pat. It makes the comparison far more stringent. 7. The Golden Nugget 💰 12 pat. mBBB + 10 pat. uBBB gives Curasight the opportunity to compare the two groups directly and answer a very concrete and strongly value-driving question: Is BBB opening actually necessary for uTREAT? If uBBB shows that the same tumor delivery can be achieved without mannitol, it doesn't just change the treatment – it changes the product. uTREAT then becomes a significantly simpler and less burdensome treatment for glioblastoma, which can be given to a broader group of patients and be far easier to implement in clinical practice. It is an entirely different commercial case. Big Pharma does not just pay for a therapeutic radioligand product to work. They pay for the value the product creates - and this is precisely where the value is significantly boosted. We have received positive readout data, and exciting topline data is on the way in H1. The case is not just intact - but stands before a massive change in value! 🚀 Data is King - we need to see it! ⚡Information hierarchy..!! 😁 Who the f..... Cares about that One must say that there are enough Alphas here to write a folkeskole ADHD textbook, but is there anyone who can give me an answer on whether this "Case" IH holds up or should I just buy a John Deere!!! Thinking the latter atm
- ·1.10.InStock pointed out that the protocol change has now been approved (30/9). Now it will be exciting to hear the wording / PM of this - and then it is just to get started 😉Why on earth is there not coming any PM/BM from management? There is practically radio silence. An announcement about the approval could at least come. Or is it not big enough and worth the trouble?
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 224 | NON | DDB | ||
| 76 | NON | DDB | ||
| 195 | SSWM | PAS | ||
| 100 | SSWM | DDB | ||
| 500 | SSWM | PAS |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Rahastot ja ETF:t, joilla on osaketta
Mikään rahasto ei ilmoita osaketta kymmenen suurimman omistuksensa joukossa.
Asiakkaat katsoivat myös
Välittäjätilasto
Ostaneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Nordnet Bank AB | 13 025 | 1 167 | 11 858 | 97 |
| SSW Market Making GmbH | 9 647 | 9 442 | 205 | 0 |
| Avanza Bank AB | 0 | 249 | −249 | 0 |
| Pareto Securities AS | 3 393 | 6 073 | −2 680 | 0 |
| Danske Bank A/S | 660 | 9 794 | −9 134 | 0 |
Myyneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Danske Bank A/S | 660 | 9 794 | −9 134 | 0 |
| Pareto Securities AS | 3 393 | 6 073 | −2 680 | 0 |
| Avanza Bank AB | 0 | 249 | −249 | 0 |
| SSW Market Making GmbH | 9 647 | 9 442 | 205 | 0 |
| Nordnet Bank AB | 13 025 | 1 167 | 11 858 | 97 |